Oral Valganciclovir treatment in a CMV congenital infected infant with sensorineural hearing loss (SNHL) first detected at 4 months of age.

Klinische Pädiatrie

Volumn 221, Issue 7, 2009, Pages 448-449

  Hilgendorff, A ^a   Daiminger, A ^a   Dangel, V ^a   Kreuder, J ^a   Geidel, C ^a   Reiss, I ^a   Enders, G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DRUG DERIVATIVE; GANCICLOVIR; VALGANCICLOVIR;

ARTICLE; CASE REPORT; CYTOMEGALOVIRUS INFECTION; FOLLOW UP; HUMAN; INFANT; LONG TERM CARE; MALE; NEWBORN; NEWBORN SCREENING; OFF LABEL DRUG USE; ORAL DRUG ADMINISTRATION; PERCEPTION DEAFNESS; PREMATURITY; PRESCHOOL CHILD;

ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; CHILD, PRESCHOOL; CYTOMEGALOVIRUS INFECTIONS; FOLLOW-UP STUDIES; GANCICLOVIR; HEARING LOSS, SENSORINEURAL; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; LONG-TERM CARE; MALE; NEONATAL SCREENING; OFF-LABEL USE;

EID: 77949463045     PISSN: None     EISSN: 14393824     Source Type: Journal    
DOI: 10.1055/s-0029-1234076     Document Type: Article

References (0)